Dominic Walsh joined Biogen in September 2018 and is the head of the Neurodegeneration Research Unit (NDRU) where he’s responsible for overseeing Biogen’s research efforts on AD, PD and HD. Dominic has worked on the molecular aspects of neurodegeneration since December 1991. He has authored over 150 research articles, written a number of widely cited reviews and given over 100 invited lectures and webinars. He has served as an Editor or Editorial Advisor for several journals and as an ad hoc reviewer for all the world’s leading biomedical journals. Dominic has also served as a consultant and/or SAB member for several pharmaceutical companies and biotechs. Prior to joining Biogen his research was supported by multiple agencies, grants from industry and donations from the public. He was named one of The World’s Most Influential Scientific Minds by Thomson Reuters and ranked among the top 1% of researchers in the field of Neuroscience and Behavior 2014–2016.
Where are we as a nation on the path to the 2025 goal of stopping Alzheimer’s disease? Since the disease was first identified in the early 1900s, innovation has been slow, but the pace of science and discovery is dramatically increasing. This session will explore the progress made to date and the potential ahead for the development of new treatments, innovative diagnostics and means of prevention.
